Beta-Amino Acid Polypeptides for Enzymatic Degradation Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Natural polypeptides, such as those from the secretin family, cytokines, and apolipoproteins, have short half-lives and are prone to degradation, limiting their bioavailability and therapeutic efficacy due to rapid enzymatic breakdown, necessitating the development of more stable and bioactive analogs with enhanced conformational constraints or flexibility for improved pharmaceutical applications.
Innovation Solution
Synthesis of helical polypeptides incorporating a repeated pattern of β-amino acids along the polypeptide chain, which increases conformational rigidity and resistance to degradation, thereby extending half-life and preserving native binding interfaces, while maintaining or exceeding the biological activity of their natural counterparts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If natural polypeptide sequences are used, then biological activity is maintained, but half-life is short and degradation resistance is poor
Solution Approach 1:
The patent applies parameter changes by substituting specific amino acid residues with chemically modified analogs (e.g., norleucine, norvaline, cyclohexylalanine) that have altered side chain properties. These parameter changes in molecular structure increase resistance to proteolytic degradation while preserving the polypeptide's ability to bind to its target receptor, thereby extending half-life without sacrificing biological activity
Solution Approach 2:
The patent creates composite polypeptide structures by combining natural amino acid residues with non-natural chemically modified residues in specific patterns. This composite approach allows the molecule to maintain regions necessary for receptor recognition while incorporating degradation-resistant segments, achieving both biological activity and extended stability
2Stability of the object's composition
If polypeptide stability is increased through chemical modification, then half-life is extended, but structural complexity increases
Solution Approach 1:
The patent applies local quality by making targeted chemical modifications at specific positions within the polypeptide chain rather than uniformly modifying the entire structure. For example, substituting only certain hydrophobic residues or surface-exposed residues with degradation-resistant analogs while leaving other regions unchanged. This localized approach increases stability where needed while minimizing overall structural complexity and maintaining regions critical for biological function
3Reliability
If natural polypeptides are administered, then bioactivity is achieved, but enzymatic degradation occurs rapidly
Solution Approach 1:
The patent creates modified copies of natural polypeptides that replicate the essential features required for biological activity (such as key side chains involved in receptor binding) while incorporating degradation-resistant chemical modifications. These copied structures maintain the pharmacophore elements necessary for bioactivity but are engineered to resist proteolytic enzymes, thereby extending therapeutic duration
Data Source
AI summary
This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.